A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

What Was Tested

The trial (not phased) is built around Tirzepatide for fat loss, obesity & body recomposition.

Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975.

It had two arms (groups): Tirzepatide [weight loss arm] (experimental) and Lifestyle advice and anti-hypertensive medications [standard of Care arm] (active comparator).

6 months of treatment with a combined GLP-1/GIP receptor agonist, tirzepatide.

The registry classes the interventions as drug.

Who Took Part

The registry lists 60 planned participants were the target.

It was open to people of any sex aged from 18 years up to 40 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Aged 18 to 40 years (inclusive). Body mass index (BMI) ≥27 kg/m2. Clinical diagnosis of primary (essential) hypertension as per NICE guidance. Unattended brachial SBP ≥135 and/or DBP ≥85 mmHg and \<160/100 mmHg. Maximum of one antihypertensive medication.

The full record lists 5 inclusion and 29 exclusion criteria; among the exclusions: written informed consent; aged 18 to 40 years (inclusive); body mass index ≥27 kg/m2.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the fat loss, obesity & body recomposition participants stayed in one arm throughout.

Nothing was hidden in this open-label Tirzepatide study: the fat loss, obesity & body recomposition participants and staff both knew the treatment.

It started in 2026-01 with completion listed for 2027-01.

It ran at 1 site in United Kingdom.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Ambulatory systolic blood pressure (time frame: Baseline to week 24).

It also tracked 55 secondary outcomes, for example Ambulatory diastolic blood pressure, Clinic systolic blood pressure, Clinic diastolic blood pressure, Clinic mean arterial pressure, Unattended systolic blood pressure and Unattended diastolic blood pressure.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Tirzepatide in 60 people with fat loss, obesity & body recomposition.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, Fat loss, obesity & body recomposition research.